Insider Buying: The Oncology Institute, Inc. (NASDAQ:TOI) CEO Buys 22,640 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) CEO Daniel Virnich bought 22,640 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of $1.04 per share, for a total transaction of $23,545.60. Following the completion of the transaction, the chief executive officer now owns 724,363 shares in the company, valued at $753,337.52. This represents a 3.23 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Oncology Institute Stock Up 2.7 %

Shares of TOI opened at $1.14 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 5.91. The company has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $0.48. The stock has a market cap of $86.14 million, a price-to-earnings ratio of -1.46 and a beta of 0.41. The Oncology Institute, Inc. has a 12 month low of $0.13 and a 12 month high of $1.63.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The company had revenue of $100.27 million during the quarter, compared to analyst estimates of $109.15 million.

Institutional Investors Weigh In On Oncology Institute

Institutional investors and hedge funds have recently made changes to their positions in the company. HighTower Advisors LLC lifted its holdings in Oncology Institute by 190.8% during the 3rd quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock valued at $27,000 after purchasing an additional 53,382 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Oncology Institute by 613.6% during the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after buying an additional 109,769 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Oncology Institute in the fourth quarter valued at approximately $41,000. Renaissance Technologies LLC boosted its holdings in shares of Oncology Institute by 7.1% in the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after acquiring an additional 12,000 shares in the last quarter. Finally, FreeGulliver LLC grew its position in Oncology Institute by 219.3% during the 4th quarter. FreeGulliver LLC now owns 600,747 shares of the company’s stock worth $186,000 after acquiring an additional 412,578 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.